Cargando…

Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes

PURPOSE: Estrogen-receptor (ER) and progesterone-receptor (PR) expression levels in breast cancer, which have been principally compared via binomial descriptors, can vary widely across tumors. We sought to characterize ER and PR expression levels using semi-quantitative analyses of receptor staining...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Grace, Teng, Mingxiang, Rosa, Marilin, Wang, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822747/ https://www.ncbi.nlm.nih.gov/pubmed/35135604 http://dx.doi.org/10.1186/s13058-022-01507-1

Ejemplares similares

CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
por: Stolarova, Lenka, et al.
Publicado: (2020)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition
por: Kumpula, Timo A., et al.
Publicado: (2023)

First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer
por: Tedaldi, Gianluca, et al.
Publicado: (2014)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation
por: Xie, Changqing, et al.
Publicado: (2018)

Germline mutation of CHEK2 in neurofibromatosis 1 and 2: Two case reports
por: Li, Qiang, et al.
Publicado: (2018)

The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
por: Mandelker, Diana, et al.
Publicado: (2019)

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Stolarova, Lenka, et al.
Publicado: (2023)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer
por: Alanazi, Ibrahim O., et al.
Publicado: (2021)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

Germline Structural Variations in Cancer Predisposition Genes
por: Pócza, Tímea, et al.
Publicado: (2021)

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma
por: Havranek, Ondrej, et al.
Publicado: (2015)

The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation
por: Li, Xueen, et al.
Publicado: (2022)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Pathogenic Germline BRCA1/2 Mutations and Familial Predisposition to Gastric Cancer
por: Ichikawa, Hiroshi, et al.
Publicado: (2018)

Germline polymorphisms of circadian genes and gastric cancer predisposition
por: Rajendran, Senthilkumar, et al.
Publicado: (2020)

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series
por: Sukumar, Jasmine, et al.
Publicado: (2021)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Germline predisposition to genitourinary rhabdomyosarcoma
por: Schneider, Kami Wolfe, et al.
Publicado: (2020)

Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas
por: Gao, Yinjie, et al.
Publicado: (2021)

Case report: Two sisters with a germline CHEK2 variant and distinct endocrine neoplasias
por: Vallera, Raphaelle D., et al.
Publicado: (2022)

Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
por: Kirchner, Kira, et al.
Publicado: (2023)

Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer
por: Srivastava, Aayushi, et al.
Publicado: (2021)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition
por: Chan, Sock Hoai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_japb1ljmd78n5pp2ahjbsh733t